We are live on ! Find out more
BCRX icon

BioCryst Pharmaceuticals
BCRX

233 hedge funds and large institutions have $1.24B invested in BioCryst Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 101 increasing their positions, 57 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

287% more call options, than puts

Call options by funds: $22.4M | Put options by funds: $5.79M

77% more repeat investments, than reductions

Existing positions increased: 101 | Existing positions reduced: 57

1% more capital invested

Capital invested by funds: $1.23B → $1.24B (+$18.3M)

0.61% more ownership

Funds ownership: 92.14% → 92.75% (+0.61%)

0% more funds holding in top 10

Funds holding in top 10: 6 → 6 (0)

5% less first-time investments, than exits

New positions opened: 21 | Existing positions closed: 22

1% less funds holding

Funds holding: 236 → 233 (-3)

Holders
233
Holders Change
-3
Holders Change %
-1.27%
% of All Funds
3.7%
Holding in Top 10
6
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.1%
New
21
Increased
101
Reduced
57
Closed
22
Calls
$22.4M
Puts
$5.79M
Net Calls
+$16.6M
Net Calls Change
+$3.11M

Top Buyers

1
B
Braidwell
Connecticut
+$18.5M
2
DM
Deerfield Management
New York
+$14.1M
3
N
Nuveen
North Carolina
+$11.3M
4
BlackRock
BlackRock
New York
+$9.19M
5
Morgan Stanley
Morgan Stanley
New York
+$6.87M

Top Sellers

1
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
-$30.3M
2
State Street
State Street
Massachusetts
-$12.9M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
-$8.95M
4
Fisher Asset Management
Fisher Asset Management
Washington
-$8.19M
5
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$4.93M
Name Holding Trade Value Shares
Change 		Change in
Stake
CSS
51
Cubist Systematic Strategies
Connecticut
$4.6M +$162K +22,533 +4%
Ameriprise
52
Ameriprise
Minnesota
$4.6M +$49.4K +6,876 +1%
Osaic Holdings
53
Osaic Holdings
Arizona
$4.6M +$332K +46,229 +8%
AA
54
AlphaCentric Advisors
Puerto Rico
$4.59M +$568K +79,000 +14%
Jane Street
55
Jane Street
New York
$4.38M +$1.37M +190,826 +45%
JP Morgan Chase
56
JP Morgan Chase
New York
$4.31M -$165K -23,000 -4%
TI
57
Trexquant Investment
Connecticut
$4.2M +$1.85M +257,094 +77%
OIM
58
Oracle Investment Management
Connecticut
$3.93M – – –
Barclays
59
Barclays
United Kingdom
$3.88M -$17.3K -2,411 -0.4%
BNP Paribas Financial Markets
60
BNP Paribas Financial Markets
France
$3.84M +$2.35M +327,226 +152%
Connor, Clark & Lunn Investment Management (CC&L)
61
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$3.84M +$1.02M +141,567 +35%
Jacobs Levy Equity Management
62
Jacobs Levy Equity Management
New Jersey
$3.33M -$4.93M -685,586 -59%
Swiss National Bank
63
Swiss National Bank
Switzerland
$2.94M +$35.9K +5,000 +1%
Balyasny Asset Management
64
Balyasny Asset Management
Illinois
$2.89M +$2.93M +408,297 New
JF
65
Jump Financial
Illinois
$2.87M +$2.29M +319,037 +372%
Legal & General Group
66
Legal & General Group
United Kingdom
$2.73M +$152K +21,217 +6%
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
67
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Ontario, Canada
$2.72M +$2.76M +384,000 New
Citigroup
68
Citigroup
New York
$2.63M +$139K +19,329 +5%
Voloridge Investment Management
69
Voloridge Investment Management
Florida
$2.43M +$1.81M +252,451 +276%
Susquehanna International Group
70
Susquehanna International Group
Pennsylvania
$2.26M -$709K -98,664 -24%
UBS Group
71
UBS Group
Switzerland
$2.17M -$782K -108,883 -26%
RhumbLine Advisers
72
RhumbLine Advisers
Massachusetts
$2.09M -$133K -18,559 -6%
PP
73
PDT Partners
New York
$1.92M +$515K +71,630 +36%
UOC
74
UBS O'Connor
Illinois
$1.71M +$67.2K +9,357 +4%
UBS AM
75
UBS AM
Illinois
$1.67M – – –
1 2
3
4 5

BCRX Hedge Fund Activity: Q3 2023 in Review

233 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in BioCryst Pharmaceuticals (BCRX) for Q3 2023, worth a combined $1.24B — up 1.5% from $1.23B a quarter earlier.

Sellers outnumbered buyers: 22 funds closed out of BCRX and 21 opened new positions — a net loss of 1 holder — while 57 trimmed existing stakes and 101 added.

The largest buyer was Braidwell, adding an estimated $18.5M. The largest seller was Assenagon Asset Management, cutting an estimated $30.3M.

  • 233 institutional investors held BioCryst Pharmaceuticals (BCRX) as of Q3 2023, down from 236 in Q2 2023.
  • Funds reported $1.24B of BioCryst Pharmaceuticals stock for Q3 2023, up 1.5% quarter-over-quarter.
  • 21 funds opened new BioCryst Pharmaceuticals positions in Q3 2023 and 22 closed out, a net change of -1 holder.
  • The largest BioCryst Pharmaceuticals buyer in Q3 2023 was Braidwell, an estimated $18.5M added.
  • The largest BioCryst Pharmaceuticals seller in Q3 2023 was Assenagon Asset Management, an estimated $30.3M sold.

Based on aggregated 13F filings for Q3 2023.